Drug Discovery & DDS– category –
-
Penn Engineering Develops LNP-Based ‘One-Two Punch’ to Transform Oral Cancer Treatment: Co-Delivering p53 & Ciclopirox Significantly Reduces Tumor Burden in Resistant Models
Penn Engineering (University of Pennsylvania) USA Overview Researchers at Penn have developed a lipid nanoparticle (LNP) formulation to co-deliver two drugs, p53 and ciclopirox, for oral cancer treatment. This LNP platform aims to simult... -
PROTAC Research Shifts to Structural Design, Oral Bioavailability, and AI-Driven Approaches: Bibliometric Analysis Reveals Emerging Frontiers and Pivotal Trial Era
PubMed USA Overview A bibliometric analysis of 2,630 PROTAC publications from 2001-2025 reveals a shift from early E3 ligase recruitment research to current hotspots including structural basis, ternary complex design, EGFR-directed degra... -
FDA Approval of First PROTAC Vepdegestrant Raises New Challenges in Targeted Protein Degradation Patent Strategy
Elkington and Fife UK Overview The FDA approval of vepdegestrant, the first PROTAC, marks a significant milestone for targeted protein degradation (TPD), bringing complex intellectual property considerations to the forefront. The unique ... -
GLP-1 Receptor Agonist Research Rapidly Expanding Across MASLD–MASH–HCC Continuum: US Leads, China Shows Rapid Growth
Frontiers Switzerland Overview Research on GLP-1 Receptor Agonists (GLP-1RAs) in the context of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), MASH (Metabolic Dysfunction-Associated Steatohepatitis), and HCC (Hepatocel... -
Oral GLP-1 Drugs May Quash Brain’s Food Craving Circuit, NIH-Funded Study Suggests Role in Hedonic Eating and Addiction
ScienceDaily USA Overview A study funded by the NIH suggests that newer oral small-molecule GLP-1 drugs, such as orforglipron and danuglipron, may reduce hedonic feeding (eating for pleasure) by affecting a reward circuit in the brain. T... -
Daiichi Sankyo & AstraZeneca’s Datroway Approved in EU as Only TROP2-Directed Medicine with Overall Survival Benefit for 1st-Line Metastatic TNBC Patients Ineligible for Immunotherapy
Business Wire USA Overview Datroway, a TROP2-directed antibody-drug conjugate (ADC) by Daiichi Sankyo and AstraZeneca, received EU approval for first-line treatment of metastatic triple-negative breast cancer (TNBC) patients not eligible... -
Allogene Therapeutics’ Off-the-Shelf CAR T Cema-Cel Receives FDA RMAT & Fast Track Designations for First-Line MRD-Positive LBCL, Achieves 58.3% MRD-Negativity in Phase 2 Interim Analysis
Allogene Therapeutics Press Release USA Overview Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel), an off-the-shelf anti-CD19 CAR T-cell therapy, received both Regenerative Medicine Advanced Therapy (RMAT) and ... -
Henlius Initiates First-in-Human Dosing for STEAP1×CD3×CD28 Trispecific TCE HLX3902 in Metastatic Castration-Resistant Prostate Cancer and Advanced Solid Tumors
Henlius Biotech Press Release China Overview Shanghai Henlius Biotech announced the first patient dosing in a first-in-human (FIH) study for HLX3902, a trispecific T-cell engager (TCE) targeting STEAP1×CD3×CD28. This innovative trispecif... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
LNP-Delivered Multi-Specific CAR mRNA Engineering Platform Advances: Enables Controllable In Vivo CAR Expression, Overcomes Autologous Cell Manufacturing Challenges
Ace Therapeutics Unknown Overview A lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) therapy platform is advancing as a novel strategy to generate CAR-expressing immune cells in vivo. This approach allows for transient and contro...
